The adaptive immune system has the capacity to elicit anti-cancer CD4+ and CD8+ T-cell responses, which are triggered by the presentation of cancer-derived antigens as human leukocyte antigen-binding peptides (HLAp) and their recognition by cognate T-cell receptors. This evidence concerns the gene CD4 and cancer.